3 hrs ago
Applied Clinical Trials
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients...
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design , has initiated a Phase 2 clinical study with PSX1002 that will ... (more)
Tue May 21, 2013
Improved Quality of Life Is Major Unmet Need in COPD Treatment, Survey Finds
In a survey conducted by Decision Resources, a research and advisory firm located in Burlington, Massachusetts, U.S. and European pulmonologists agree that therapies offering a greater effect on quality of life are among the areas of highest unmet need in the treatment of chronic obstructive pulmonary disease .
Mon May 20, 2013
Combined wood and tobacco smoke exposure increases risk and symptoms of COPD
ATS 2013, PHILADELPHIA People who are consistently exposed to both wood smoke and tobacco smoke are at a greater risk for developing chronic obstructive pulmonary disease and for experiencing more frequent and severe symptoms of the disease, as well as more severe airflow obstruction, than those who are exposed to only one type of smoke, according ... (more)
COPD Foundation Hosts COPD8USA Conference, Highlights Latest...
WASHINGTON & CHICAGO -- -- The COPD Foundation will host COPD8USA , a multi-disciplinary, Continuing Medical Education conference, June 14-15, 2013, Hilton Chicago, 720 S. Michigan Ave., Chicago, Ill.
Sun May 19, 2013
The Motley Fool
The 3 Deadliest Diseases in the U.S.
The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... There's good news and bad news for Americans.
Mon May 13, 2013
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment...
Pearl Therapeutics Inc. today announced the initiation of PINNACLE, a global Phase 3 program of PT003 , the Company's fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist and formoterol fumarate, a long-acting beta-2 agonist , delivered via a pressurized hydrofluoroalkane using the Company's novel co-suspension formulation ... (more)
UPDATE 2-Elan strikes $1 bln royalty deal with Theravance
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline for its respiratory drugs.
Fri May 10, 2013
Us Fda approves Glaxo/Theravance drug for Copd lung disease
The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both.
Thu May 09, 2013
North Alabama medical leaders react to hospital charges data
Crestwood Medical Center in Huntsville is among hospitals across the U.S. featured in a hospital pricing report released by President Obama on Wednesday.
Sun May 05, 2013
The Motley Fool
Take a Deep Breath Before This Big FDA Decision
Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can't afford to miss.
Sat May 04, 2013
Second Phase III Study For Aclidinium And Formoterol Combination In COPD Produces Positive Results
Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial.
Thu May 02, 2013
Customer Interaction Solutions
Research and Markets: Inhalation & Nasal Spray Generic Drugs 2012
It is no surprise then, that such high revenue originator drugs are attracting interest from prospective generic competitors.
Positive Phase III Results With Aclidinium/Formoterol in COPD
Positive results have been reported from the AUGMENT/COPD trial, the second 6-month pivotal phase III study of investigational fixed-dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.
Wed May 01, 2013
For many of the 12 million Americans with chronic obstructive pulmonary disease or COPD, breathlessness, coughing and mucus production may not be symptoms of a nagging cold, but serious, daily effects of a progressive, irreversible lung disease that includes the respiratory illnesses chronic bronchitis and emphysema.
Customer Interaction Solutions
Forest Laboratories and Almirall Announce Positive Results for the...
Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.
Fri Apr 26, 2013
GlaxoSmithKline submits application for COPD drug in EU
GlaxoSmithKline has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease .
Thu Apr 25, 2013
Theravance to split into drug development, royalty companies
Ahead of FDA approval of its two inhaled lung drugs, Theravance Inc. said Thursday it will split into two independent companies: one to absorb royalties from those drugs' sales, the other focused on drug development.
'Awareness on chronic lung disease necessary' - Indiatalkies.com
New Delhi, April 25: Prolonged cough and breathlessness should not be taken lightly, as it can lead to chronic obstructive pulmonary disease, say experts.